Evaluation of pulmonary toxicities in lymphoma patients receiving brentuximab vedotin. Read more about Evaluation of pulmonary toxicities in lymphoma patients receiving brentuximab vedotin.
Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. Read more about Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma.
Impact of initial biopsy type on the time to final diagnostic biopsy in patients with follicular lymphoma and suspected histologic transformation. Read more about Impact of initial biopsy type on the time to final diagnostic biopsy in patients with follicular lymphoma and suspected histologic transformation.
Toci or not toci: innovations in the diagnosis, prevention, and early management of cytokine release syndrome. Read more about Toci or not toci: innovations in the diagnosis, prevention, and early management of cytokine release syndrome.
Comorbidities and socioeconomic status are predictors of survival in children and young adults with Burkitt lymphoma. Read more about Comorbidities and socioeconomic status are predictors of survival in children and young adults with Burkitt lymphoma.
Survival after autologous versus allogeneic transplantation in patients with relapsed and refractory Hodgkin lymphoma. Read more about Survival after autologous versus allogeneic transplantation in patients with relapsed and refractory Hodgkin lymphoma.
Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma. Read more about Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma.
Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: a real-world analysis of health plan enrollees. Read more about Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: a real-world analysis of health plan enrollees.
Incidence, management and outcomes of arterial and venous thrombosis after chimeric antigen receptor modified T cells for B cell lymphoma and multiple myeloma. Read more about Incidence, management and outcomes of arterial and venous thrombosis after chimeric antigen receptor modified T cells for B cell lymphoma and multiple myeloma.
A single-center retrospective cohort analysis of venetoclax in relapsed/refractory multiple myeloma. Read more about A single-center retrospective cohort analysis of venetoclax in relapsed/refractory multiple myeloma.
